Figure 5From: A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40Characterization of recombinant cyclin D1 fusion proteins. (A) The construction of cyclin D1 fused to DC receptor CD40 recombinant IgG4 mAb or non-DC binding IgG4 as a control. The sequence of the different human cyclin D1 protein domains is shown in different colors. (B, C) Anti-CD40-cyclin D1 Abs detected on the surface of monocytederived IFN-DCs. Flow cytometry staining of IFN-DCs with anti-human IgG (B), antihuman cyclin D1 (C), or anti-mouse IgG isotype control mAbs (C). (D) The expression of several molecules (CD86, CD80, CD83, HLA-DR, and CCR7) on the IFN-DCs was significantly increased after co-culture with anti-CD40-cyclin D1 fusion proteins for 48 h, compared with co-culture with IgG4-cyclin D1 control proteins. The data from a representative of three independent experiments are shown; different donors showed similar results.Back to article page